Stock Ratings / Health Care / SHPH / options

IMMP (60) MIRA (48) CRVO (29) CELU (34) ⌘ Pro Terminal →

Shuttle Pharmaceuticals Holdings Inc. (SHPH) Options Positioning, Max Pain & Unusual Sweeps

$5.23 -0.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.22

Shuttle Pharmaceuticals Holdings Inc. (SHPH) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $24.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.22 (-0.22%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SHPH)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY SHPH SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (33% of score)

FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 58 (BULLISH MOMENTUM)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$5.33-4.7% Next Q

Q2 (-2Q)

Grade C-$5.08-4.3% Next Q

Q3 (-1Q)

Grade D$4.86+7.6% Next Q

Current

Grade D$5.23-6.1% Hist 90D α

Trajectory: C- (54) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SHPH Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SHPH currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.18) and Max Pain ($5.49) forces dealer call-delta covering toward $46.62.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SHPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SHPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SHPH)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SHPH.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SHPH)

✓Walkthrough of SHPH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SHPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.22%▲ ASCENDING CHANNEL

2026-10-30O $5.35H $5.41L $4.80C $5.23VOL 20.5K

RES: $6.14SUP: $3.36SMA50: $4.18SMA200: $7.05

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SHPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SHPH Butterfly Map → + Track SHPH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SHPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SHPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SHPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SHPH)

Health Care Rank #460 of 1016 ⚔️ IMMP vs SHPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SHPH vs. IMMP, MIRA, CRVO, CELU)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Shuttle Pharmaceuticals Holdings Inc. (SHPH) ranks #460 by composite RQD confidence (46/100, grade D) and #819 by equity capitalization ($24.9M). Within this direct 5-issuer industry benchmark cohort, SHPH leads on earnings valuation at N/A trailing P/E, while SHPH leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IMMP currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with SHPH at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SHPH ACTIVE Shuttle Pharmaceuticals Holdings Inc.	D	46/100	—	—	-35.0%	-0.19%	$24.9M	Benchmark Subject
IMMP Immutep Limited	C-	60/100	—	—	—	+0.30%	$24.5M	/immp-vs-shph →
MIRA MIRA Pharmaceuticals Inc.	D	48/100	—	—	-35.0%	+2.79%	$24.0M	/mira-vs-shph →
CRVO CervoMed Inc.	E	29/100	—	—	-35.0%	-20.81%	$26.5M	/crvo-vs-shph →
CELU Celularity Inc. (Class A)	E	34/100	—	24.4%	-35.0%	-9.66%	$27.6M	/celu-vs-shph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001757499

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Shuttle Pharmaceuticals Holdings Inc. (SHPH) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.7M, operating cash flow of -$9.5M, and free cash flow of -$9.5M (-29.4% YoY). On the balance sheet, SHPH closed FY2025 with $10.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$11.7M	-$9.5M	-$9.5M	$10.5M	—
FY2024 (FY)	2024-12-31	$0	-$9.1M	-$7.3M	-$7.3M	$2.5M	—
FY2023 (FY)	2023-12-31	$0	-$6.6M	-$5.6M	-$5.6M	—	—

3. SHPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SHPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Shuttle Pharmaceuticals Holdings Inc. (NASDAQ: SHPH) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $5.23 (-0.19% 1D, market cap $24.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SHPH ranks #460 in composite RQD confidence.

How does SHPH compare to IMMP and MIRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SHPH carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMMP (Immutep Limited) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $24.5M) and MIRA (MIRA Pharmaceuticals Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $24.0M). Among the 5-stock peer group, SHPH leads on earnings multiple (N/A) while SHPH leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SHPH?

Per SHPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001757499), Shuttle Pharmaceuticals Holdings Inc. generated $0 in revenue, -$11.7M in net income, and -$9.5M in free cash flow against $10.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SHPH trading relative to its 50-day, 200-day, and 52-week technical levels?

SHPH last traded at $5.23 (-0.19% on volume of 5,572 shares), positioning the stock +25.12% above its 50-day simple moving average ($4.18) and -25.82% below its 200-day simple moving average ($7.05). Across its 52-week range of $2.58 to $44.40, SHPH sits at the 6.3% percentile with a 14-day RSI of 58.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.58 to $5.88).

SHPH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is SHPH's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for SHPH.

Direct Sub-Reports: SHPH RQD Cockpit SHPH 12M Forecast SHPH Earnings & Move SHPH Dividends & DRIP SHPH Insiders & 13F SHPH Whale Options SHPH Profit Sankey SHPH News & Why